A single dose of a DNA vaccine encoding Apa coencapsulated with 6,6=-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice

Clinical and Vaccine Immunology

Volumn 20, Issue 8, 2013, Pages 1162-1169

  Carlétti, Dyego ^a   Da Fonseca, Denise Morais ^a   Gembre, Ana Flávia ^a   Masson, Ana Paula ^a   Campos, Lívia Weijenborg ^a   Leite, Luciana C C ^c   Pires, Andréa Rodrigues ^d   Lannes Vieira, Joseli ^e   Silva, Célio Lopes ^b   Bonato, Vânia Luiza Deperon ^b   Horn, Cynthia ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

^d Fonte Medicina Diagnóstica Ltda   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE PROLINE ANTIGEN; BCG VACCINE; CORD FACTOR; DNA VACCINE; MICROSPHERE; MYCOBACTERIUM ANTIGEN; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; ENCAPSULATION; FEMALE; HISTOPATHOLOGY; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL LOAD; CORD FACTORS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED BALB C; MICROSPHERES; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS VACCINES; TUBERCULOSIS, PULMONARY; VACCINES, DNA;

EID: 84880894013     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00148-13     Document Type: Article

References (43)

1. World Health Organization. 2011. Global tuberculosis control: a short update to the 2011 report. World Health Organization, Geneva, Switzerland.
2. World Health Organization. 2009. Global tuberculosis control. Epidemiology, strategy, financing. World Health Organziation, Geneva, Switzerland.
3. Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, Efe S, Staveley I, Ewer K, Lalvani A. 2005. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet 366:1443-1451.
4. Sadoff JC. 2005. Vaccine risk and benefit in the developing world. Health Aff. (Millwood) 24:1379-1380.
5. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a metaanalysis and assessment of cost-effectiveness. Lancet 367:1173-1180.
6. Kaufmann SH. 2005. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26:660-667.
7. Romano M, Huygen K. 2009. DNA vaccines against mycobacterial diseases. Expert Rev. Vaccines 8:1237-1250.
8. Hubbard RD, Flory CM, Collins FM, Cocito C. 1992. Immunization of mice with the antigen A60 of Mycobacterium bovis BCG. Clin. Exp. Immunol. 88:129-131.
9. Andersen P. 1994. Effective vaccination of mice against Mycobacterium tuberculosis infection with a soluble mixture of secreted mycobacterial proteins. Infect. Immun. 62:2536-2544.
10. Roberts AD, Sonnenberg MG, Ordway DJ, Furney SK, Brennan PJ, Belisle JT, Orme IM. 1995. Characteristics of protective immunity engendered by vaccination of mice with purified culture filtrate protein antigens of Mycobacterium tuberculosis. Immunology 85:502-508.
11. Pal PG, Horwitz MA. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4781-4792.
12. Horwitz MA, Lee BW, Dillon BJ, Harth G. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92:1530-1534.
13. Verreck FA, Vervenne RA, Kondova I, van Kralingen KW, Remarque EJ, Braskamp G, van der Werff NM, Kersbergen A, Ottenhoff TH, Heidt PJ, Gilbert SC, Gicquel B, Hill AV, Martin C, McShane H, Thomas AW. 2009. MVA85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques. PLoS One 4:e5264. doi:10.1371/journal .pone.0005264.
14. Laqueyrerie A, Militzer P, Romain F, Eiglmeier K, Cole S, Marchal G. 1995. Cloning, sequencing, and expression of the apa gene coding for the Mycobacterium tuberculosis 45/47-kilodalton secreted antigen complex. Infect. Immun. 63:4003-4010.
15. Horn C, Namane A, Pescher P, Riviere M, Romain F, Puzo G, Barzu O, Marchal G. 1999. Decreased capacity of recombinant 45/47-kDa molecules (Apa) of Mycobacterium tuberculosis to stimulate T lymphocyte responses related to changes in their mannosylation pattern. J. Biol. Chem. 274:32023-32030.
16. Ragas A, Roussel L, Puzo G, Riviere M. 2007. The Mycobacterium tuberculosis cell-surface glycoprotein apa as a potential adhesin to colonize target cells via the innate immune system pulmonary C-type lectin surfactant protein A. J. Biol. Chem. 282:5133-5142.
17. Romain F, Laqueyrerie A, Militzer P, Pescher P, Chavarot P, Lagranderie M, Auregan G, Gheorghiu M, Marchal G. 1993. Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria. Infect. Immun. 61:742-750.
18. Kumar P, Amara RR, Challu VK, Chadda VK, Satchidanandam V. 2003. The Apa protein of Mycobacterium tuberculosis stimulates gamma interferon-secreting CD4- and CD8- T cells from purified protein derivative- positive individuals and affords protection in a guinea pig model. Infect. Immun. 71:1929-1937.
19. Diagbouga S, Fumoux F, Zoubga A, Sanou PT, Marchal G. 1997. Immunoblot analysis for serodiagnosis of tuberculosis using a 45/47- kilodalton antigen complex of Mycobacterium tuberculosis. Clin. Diagn. Lab. Immunol. 4:334-338.
20. Garapin A, Ma L, Pescher P, Lagranderie M, Marchal G. 2001. Mixed immune response induced in rodents by two nakedDNAgenes coding for mycobacterial glycosylated proteins. Vaccine 19:2830-2841.
21. Lima VM, Bonato VL, Lima KM, Dos Santos SA, Dos Santos RR, Goncalves ED, Faccioli LH, Brandao IT, Rodrigues-Junior JM, Silva CL. 2001. Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis. Infect. Immun. 69:5305- 5312.
22. Wang D, Robinson DR, Kwon GS, Samuel J. 1999. Encapsulation of plasmid DNA in biodegradable poly(D, L-lactic-co-glycolic acid) microspheres as a novel approach for immunogene delivery. J. Control. Release 57:9-18.
23. Lima KM, Santos SA, Lima VM, Coelho-Castelo AA, Rodrigues JM Jr, Silva CL. 2003. Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGA microspheres protects mice against a virulent strain of Mycobacterium tuberculosis. Gene Ther. 10:678-685.
24. Griffiths G, Nystrom B, Sable SB, Khuller GK. 2010. Nanobead-based interventions for the treatment and prevention of tuberculosis. Nat. Rev. Microbiol. 8:827-834.
25. Pérez O, Harandi AM. 2008. 4th International Workshop in Vaccine Adjuvants and Parasitic Vaccines (adjuvant 2008). Expert Rev. Vaccines 7:1151-1153.
26. Bonato VL, Goncalves ED, Soares EG, Santos Junior RR, Sartori A, Coelho-Castelo AA, Silva CL. 2004. Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8- cells, interferon- gamma recovery and reduction of lung injury. Immunology 113:130- 138.
27. Fonseca DM, Silva CL, Paula MO, Soares EG, Marchal G, Horn C, Bonato VL. 2007. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection. Immunology 121:508-517.
28. Sambrook J, Fritsch EF, Maniatis T. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
29. Diwan M, Park TG. 2001. Pegylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Release 73:233-244.
30. Diwan M, Park TG. 2003. Stabilization of recombinant interferon-alpha by pegylation for encapsulation in PLGA microspheres. Int. J. Pharm. 252:111-122.
31. Brennan MJ, Clagett B, Fitzgerald H, Chen V, Williams A, Izzo AA, Barker LF. 2012. Preclinical evidence for implementing a prime-boost vaccine strategy for tuberculosis. Vaccine 30:2811-2823.
32. Rodrigues LC, Pereira SM, Cunha SS, Genser B, Ichihara MY, de Brito SC, Hijjar MA, Dourado I, Cruz AA, Sant'Anna C, Bierrenbach AL, Barreto ML. 2005. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC clusterrandomised trial. Lancet 366:1290-1295.
33. Dantas OM, Ximenes RA, de Albuquerque Mde F, da Silva NL, Montarroyos UR, de Souza WV, Pereira TC, Campelo AR, Rodrigues LC. 2006. A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int. J. Tuberc. Lung Dis. 10:536-541.
34. Skinner MA, Wedlock DN, de Lisle GW, Cooke MM, Tascon RE, Ferraz JC, Lowrie DB, Vordermeier HM, Hewinson RG, Buddle BM. 2005. The order of prime boost vaccination of neonatal calves with Mycobacterium bovis BCG and a DNA vaccine encoding mycobacterial proteins hsp65, hsp70, and Apa is not critical for enhancing protection against bovine tuberculosis. Infect. Immun. 73:4441-4444.
35. Romano M, D'Souza S, Adnet PY, Laali R, Jurion F, Palfliet K, Huygen K. 2006. Priming but not boosting with plasmid DNA encoding mycolyltransferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv. Vaccine 24:e3353- e3364.
36. Ferraz JC, Stavropoulos E, Yang M, Coade S, Espitia C, Lowrie DB, Colston MJ, Tascon RE. 2004. A heterologous DNA priming- Mycobacterium bovis BCG boosting immunization strategy using mycobacterial Hsp70, Hsp65, and Apa antigens improves protection against tuberculosis in mice. Infect. Immun. 72:6945-6950.
37. Sable SB, Cheruvu M, Nandakumar S, Sharma S, Bandyopadhyay K, Kellar KL, Posey JE, Plikaytis BB, Amara RR, Shinnick TM. 2011. Cellular immune responses to nine Mycobacterium tuberculosis vaccine candidates following intranasal vaccination. PLoS One 6(7):e22718. doi: 10.1371/journal.pone.0022718.
38. Taylor JL, Turner OC, Basaraba RJ, Belisle JT, Huygen K, Orme IM. 2003. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71:2192-2198.
39. Taylor JL, Ordway DJ, Troudt J, Gonzalez-Juarrero M, Basaraba RJ, Orme IM. 2005. Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA. Infect. Immun. 73:5189-5193.
40. Lu J, Wang C, Zhou Z, Zhang Y, Cao T, Shi C, Chen Z, Chen L, Cai C, Fan X. 2011. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein. Clin. Dev. Immunol. 2011: 617892. doi:10.1155/2011/617892.
41. Moreno-Mendieta SA, Rocha-Zavaleta L, Rodriguez-Sanoja R. 2010. Adjuvants in tuberculosis vaccine development. FEMS Immunol. Med. Microbiol. 58:75-84.
42. Jiang W, Gupta RK, Deshpande MC, Schwendeman SP. 2005. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57:391-410.
43. de Paula L, Silva CL, Carlos D, Matias-Peres C, Sorgi CA, Soares EG, Souza PR, Blades CR, Galleti FC, Bonato VL, Goncalves ED, Silva EV, Faccioli LH. 2007. Comparison of different delivery systems of DNA vaccination for the induction of protection against tuberculosis in mice and guinea pigs. Genet. Vaccines Ther. 5:2.